These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 26921287)

  • 1. Fibrin deposition following bile duct injury limits fibrosis through an αMβ2-dependent mechanism.
    Joshi N; Kopec AK; Ray JL; Cline-Fedewa H; Nawabi A; Schmitt T; Nault R; Zacharewski TR; Rockwell CE; Flick MJ; Luyendyk JP
    Blood; 2016 Jun; 127(22):2751-62. PubMed ID: 26921287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrin(ogen) drives repair after acetaminophen-induced liver injury via leukocyte α
    Kopec AK; Joshi N; Cline-Fedewa H; Wojcicki AV; Ray JL; Sullivan BP; Froehlich JE; Johnson BF; Flick MJ; Luyendyk JP
    J Hepatol; 2017 Apr; 66(4):787-797. PubMed ID: 27965156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-dependent effects of alpha-naphthylisothiocyanate disconnect biliary fibrosis from hepatocellular necrosis.
    Joshi N; Ray JL; Kopec AK; Luyendyk JP
    J Biochem Mol Toxicol; 2017 Jan; 31(1):1-7. PubMed ID: 27605088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coagulation-driven platelet activation reduces cholestatic liver injury and fibrosis in mice.
    Joshi N; Kopec AK; O'Brien KM; Towery KL; Cline-Fedewa H; Williams KJ; Copple BL; Flick MJ; Luyendyk JP
    J Thromb Haemost; 2015 Jan; 13(1):57-71. PubMed ID: 25353084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphocytes contribute to biliary injury and fibrosis in experimental xenobiotic-induced cholestasis.
    Joshi N; Kopec AK; Cline-Fedewa H; Luyendyk JP
    Toxicology; 2017 Feb; 377():73-80. PubMed ID: 28049044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The antifibrinolytic drug tranexamic acid reduces liver injury and fibrosis in a mouse model of chronic bile duct injury.
    Joshi N; Kopec AK; Towery K; Williams KJ; Luyendyk JP
    J Pharmacol Exp Ther; 2014 Jun; 349(3):383-92. PubMed ID: 24633426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin alphaMbeta2 binding motif.
    Flick MJ; LaJeunesse CM; Talmage KE; Witte DP; Palumbo JS; Pinkerton MD; Thornton S; Degen JL
    J Clin Invest; 2007 Nov; 117(11):3224-35. PubMed ID: 17932565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrinogen deficiency increases liver injury and early growth response-1 (Egr-1) expression in a model of chronic xenobiotic-induced cholestasis.
    Luyendyk JP; Kassel KM; Allen K; Guo GL; Li G; Cantor GH; Copple BL
    Am J Pathol; 2011 Mar; 178(3):1117-25. PubMed ID: 21356363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early growth response factor-1 limits biliary fibrosis in a model of xenobiotic-induced cholestasis in mice.
    Sullivan BP; Cui W; Copple BL; Luyendyk JP
    Toxicol Sci; 2012 Mar; 126(1):267-74. PubMed ID: 22094456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amelioration of Duchenne muscular dystrophy in mdx mice by elimination of matrix-associated fibrin-driven inflammation coupled to the αMβ2 leukocyte integrin receptor.
    Vidal B; Ardite E; Suelves M; Ruiz-Bonilla V; Janué A; Flick MJ; Degen JL; Serrano AL; Muñoz-Cánoves P
    Hum Mol Genet; 2012 May; 21(9):1989-2004. PubMed ID: 22381526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo.
    Flick MJ; Du X; Witte DP; Jirousková M; Soloviev DA; Busuttil SJ; Plow EF; Degen JL
    J Clin Invest; 2004 Jun; 113(11):1596-606. PubMed ID: 15173886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elimination of the fibrinogen integrin α
    Nasimuzzaman M; Arumugam PI; Mullins ES; James JM; VandenHeuvel K; Narciso MG; Shaw MA; McGraw S; Aronow BJ; Malik P
    Blood Adv; 2019 May; 3(9):1519-1532. PubMed ID: 31076408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biliary epithelial cell proliferation following alpha-naphthylisothiocyanate (ANIT) treatment: relationship to bile duct obstruction.
    Kossor DC; Goldstein RS; Ngo W; DeNicola DB; Leonard TB; Dulik DM; Meunier PC
    Fundam Appl Toxicol; 1995 Jun; 26(1):51-62. PubMed ID: 7657062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue factor-dependent coagulation contributes to alpha-naphthylisothiocyanate-induced cholestatic liver injury in mice.
    Luyendyk JP; Cantor GH; Kirchhofer D; Mackman N; Copple BL; Wang R
    Am J Physiol Gastrointest Liver Physiol; 2009 Apr; 296(4):G840-9. PubMed ID: 19179621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic liver injury drives non-traditional intrahepatic fibrin(ogen) crosslinking via tissue transglutaminase.
    Poole LG; Pant A; Baker KS; Kopec AK; Cline-Fedewa HM; Iismaa SE; Flick MJ; Luyendyk JP
    J Thromb Haemost; 2019 Jan; 17(1):113-125. PubMed ID: 30415489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Von Willebrand factor exerts hepatoprotective effects in acute but not chronic cholestatic liver injury in mice.
    Poole LG; Fournier AK; Cline-Fedewa HM; Kopec AK; Luyendyk JP; Groeneveld DJ
    Toxicology; 2021 Nov; 463():152968. PubMed ID: 34619301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of fibrinogen and protease-activated receptors in acute xenobiotic-induced cholestatic liver injury.
    Luyendyk JP; Mackman N; Sullivan BP
    Toxicol Sci; 2011 Jan; 119(1):233-43. PubMed ID: 20974703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bile duct obstruction is not a prerequisite for type I biliary epithelial cell hyperplasia.
    Kossor DC; Meunier PC; Dulik DM; Leonard TB; Goldstein RS
    Toxicol Appl Pharmacol; 1998 Oct; 152(2):327-38. PubMed ID: 9853002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited role for CXC chemokines in the pathogenesis of alpha-naphthylisothiocyanate-induced liver injury.
    Xu J; Lee G; Wang H; Vierling JM; Maher JJ
    Am J Physiol Gastrointest Liver Physiol; 2004 Sep; 287(3):G734-41. PubMed ID: 15130876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of PAR-4 and P2Y12 receptor-mediated platelet activation produces distinct hepatic pathologies in experimental xenobiotic-induced cholestatic liver disease.
    Joshi N; Kopec AK; Ray JL; Luyendyk JP
    Toxicology; 2016 Jul; 365():9-16. PubMed ID: 27475285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.